| **Supplementary Table 1.** Summary of articles included in analysis. | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Mortality Strata** | **Country** | **Vaccine** | **Gavi eligible** | **Year of publication** | **Number of surveillance years after introduction** | **Coverage\* [1]** | **Reference** |
| Low | Australia | RV5 | No | 2010 | 2 | 81 | [2] |
| Low | Australia | RV1 | No | 2011 | 3 | 82 | [3] |
| Low | Australia | Both | No | 2012 | 3 | 84 | [4] |
| Low | Australia | RV1 | No | 2014 | 6 | 84 | [5] |
| Low | Australia | RV1 | No | 2015 | 5 | 85 | [6] |
| Low | Austria | Both | No | 2010 | 1 | 47 | [7] |
| Low | Austria | Both | No | 2011 | 2 | 61 | [8] |
| Low | Austria | Both | No | 2013 | 4 | 61 | [9] |
| Low | Austria | Both | No | 2013 | 2 | 61 | [10] |
| Low | Belgium | Both | No | 2010 | 3 |  | [11] |
| Low | Belgium | Both | No | 2011 | 3 |  | [12] |
| Low | Belgium | Both | No | 2013 | 4 | 77 | [13] |
| Low | Belgium | Both | No | 2016 | 9 | 88 | [14] |
| Low | Canada | RV1 | No | 2016 | 3 |  | [15] |
| Low | Canada | RV1 | No | 2016 | 2 |  | [16] |
| Low | Finland | RV5 | No | 2012 | 1 |  | [17] |
| Low | United Kingdom | RV1 | No | 2016 | 2 | 89 | [18] |
| Low | United Kingdom | RV1 | No | 2016 | 2 | 89 | [19] |
| Low | United Kingdom | RV1 | No | 2016 | 1 | 89 | [20] |
| Low | US | RV5 | No | 2010 | 3 | 44 | [21] |
| Low | US | Both | No | 2010 | 3 | 44 | [22] |
| Low | US | Both | No | 2010 | 3 | 44 | [23] |
| Low | US | Both | No | 2011 | 3 | 44 | [24] |
| Low | US | Both | No | 2011 | 3 | 44 | [25] |
| Low | US | Both | No | 2012 | 4 | 59 | [26] |
| Low | US | Both | No | 2014 | 6 | 67 | [27] |
| Low | US | Both | No | 2015 | 6 | 67 | [28] |
| Low | US | Both | No | 2015 | 7 | 69 | [29] |
| Low | US | Both | No | 2016 | 8 | 73 | [30] |
| Medium | Armenia | RV1 | No | 2016 | 3 | 93 | [31] |
| Medium | Brazil | RV1 | No | 2010 | 3 | 81 | [32] |
| Medium | Brazil | RV1 | No | 2011 | 4 | 86 | [33] |
| Medium | Brazil | RV1 | No | 2011 | 4 | 86 | [34] |
| Medium | Brazil | RV1 | No | 2015 | 5 | 83 | [35] |
| Medium | Brazil | RV1 | No | 2015 | 4 | 86 | [36] |
| Medium | Brazil | RV1 | No | 2016 | 5 | 83 | [37] |
| Medium | Brazil | RV1 | No | 2016 | 4 | 86 | [38] |
| Medium | El Salvador | RV1 | No | 2013 | 5 | 90 | [39] |
| Medium | El Salvador | RV1 | No | 2015 | 3 | 62 | [36] |
| Medium | Mexico | RV1 | No | 2010 | 2 | 93 | [40] |
| Medium | Mexico | RV1 | No | 2013 | 5 | 98 | [41] |
| Medium | Mexico | RV1 | No | 2014 | 5 | 98 | [42] |
| Medium | Mexico | Both | No | 2015 | 3 | 93 | [36] |
| Medium | Mexico | Both | No | 2016 | 8 | 85 | [43] |
| Medium | Moldova | RV1 | No | 2016 | 2 | 69 | [44] |
| Medium | Panama | RV1 | No | 2011 | 3 | 74 | [45] |
| Medium | Panama | RV1 | No | 2011 | 3 | 74 | [46] |
| Medium | Panama | RV1 | No | 2015 | 4 | 78 | [36] |
| Medium | Venezuela | RV1 | No | 2013 | 4 | 54 | [39] |
| High | Bolivia | RV1 | Yes | 2013 | 2 | 87 | [39] |
| High | Botswana | RV1 | No | 2016 | 2 | 82 | [47] |
| High | Ghana | RV1 | Yes | 2014 | 2 | 98 | [48] |
| High | Ghana | RV1 | Yes | 2016 | 3 | 98 | [49] |
| High | Honduras | RV1 | Yes | 2013 | 2 | 98 | [39] |
| High | Malawi | RV1 | Yes | 2016 | 3 | 84 | [50] |
| High | Morocco | RV1 | No | 2015 | 3 | 90 | [51] |
| High | Nicaragua | RV5 | Yes | 2015 | 3 | 94 | [36] |
| High | Rwanda | RV5 | Yes | 2016 | 3 | 98 | [52] |
| High | South Africa | RV1 | No | 2016 | 5 | 72 | [53] |
| High | Tanzania | RV1 | Yes | 2016 | 3 | 85 | [54] |
| High | Togo | RV1 | Yes | 2016 | 1 | 85 | [55] |
| High | Yemen | RV1 | Yes | 2015 | 2 | 57 | [56] |
| High | Yemen | RV1 | Yes | 2016 | 2 | 57 | [57] |
| High | Zambia | RV1 | Yes | 2016 | 3 | 73 | [58] |
| \*Coverage during the final year of surveillance. | | | | | | | |

**Supplemental References**

1. Reported estimates of rotavirus last dose coverage. Accessed January 9, 2017.

2. Field EJ, Vally H, Grimwood K, Lambert SB. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics **2010**; 126(3): e506-12.

3. Macartney KK, Porwal M, Dalton D, et al. Decline in rotavirus hospitalisations following introduction of Australia's national rotavirus immunisation programme. J Paediatr Child Health **2011**; 47(5): 266-70.

4. Dey A, Wang H, Menzies R, Macartney K. Changes in hospitalisations for acute gastroenteritis in Australia after the national rotavirus vaccination program. Med J Aust **2012**; 197(8): 453-7.

5. David RL, Kirk MD. Rotavirus gastroenteritis hospitalisations following introduction of vaccination, Canberra. Commun Dis Intell Q Rep **2014**; 38(1): E3-8.

6. Davey HM, Muscatello DJ, Wood JG, Snelling TL, Ferson MJ, Macartney KK. Impact of high coverage of monovalent human rotavirus vaccine on Emergency Department presentations for rotavirus gastroenteritis. Vaccine **2015**; 33(14): 1726-30.

7. Paulke-Korinek M, Rendi-Wagner P, Kundi M, Kronik R, Kollaritsch H. Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in austrian children. Pediatr Infect Dis J **2010**; 29(4): 319-23.

8. Paulke-Korinek M, Kundi M, Rendi-Wagner P, et al. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine **2011**; 29(15): 2791-6.

9. Paulke-Korinek M, Kollaritsch H, Aberle SW, et al. Sustained low hospitalization rates after four years of rotavirus mass vaccination in Austria. Vaccine **2013**; 31(24): 2686-91.

10. Zlamy M, Kofler S, Orth D, et al. The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections. BMC Infect Dis **2013**; 13: 112.

11. Zeller M, Rahman M, Heylen E, et al. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine **2010**; 28(47): 7507-13.

12. Raes M, Strens D, Vergison A, Verghote M, Standaert B. Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in Belgium. Pediatr Infect Dis J **2011**; 30(7): e120-5.

13. Standaert B, Gomez JA, Raes M, Debrus S, Velazquez FR, Postma MJ. Impact of rotavirus vaccination on hospitalisations in Belgium: comparing model predictions with observed data. PLoS One **2013**; 8(1): e53864.

14. Sabbe M, Berger N, Blommaert A, et al. Sustained low rotavirus activity and hospitalisation rates in the post-vaccination era in Belgium, 2007 to 2014. Euro Surveill **2016**; 21(27).

15. Gosselin V, Petit G, Gagneur A, Genereux M. Trends in severe gastroenteritis among young children according to socio-economic characteristics before and after implementation of a rotavirus vaccination program in Quebec. Can J Public Health **2016**; 107(2): e161-7.

16. Wilson SE, Rosella LC, Wang J, et al. Population-Level Impact of Ontario's Infant Rotavirus Immunization Program: Evidence of Direct and Indirect Effects. PLoS One **2016**; 11(5): e0154340.

17. Leino T, Ollgren J, Salo H, Tiihonen P, Kilpi T. First year experience of rotavirus immunisation programme in Finland. Vaccine **2012**; 31(1): 176-82.

18. Armstrong G, Gallagher N, Cabrey P, et al. A population based study comparing changes in rotavirus burden on the Island of Ireland between a highly vaccinated population and an unvaccinated population. Vaccine **2016**; 34(39): 4718-23.

19. Atchison CJ, Stowe J, Andrews N, et al. Rapid Declines in Age Group-Specific Rotavirus Infection and Acute Gastroenteritis Among Vaccinated and Unvaccinated Individuals Within 1 Year of Rotavirus Vaccine Introduction in England and Wales. J Infect Dis **2016**; 213(2): 243-9.

20. Forrest R, Jones L, Willocks L, Hardie A, Templeton K. Impact of the introduction of rotavirus vaccination on paediatric hospital admissions, Lothian, Scotland: a retrospective observational study. Arch Dis Child **2016**.

21. Begue RE, Perrin K. Reduction in gastroenteritis with the use of pentavalent rotavirus vaccine in a primary practice. Pediatrics **2010**; 126(1): e40-5.

22. Chang HG, Smith PF, Tserenpuntsag B, Markey K, Parashar U, Morse DL. Reduction in hospitalizations for diarrhea and rotavirus infections in New York state following introduction of rotavirus vaccine. Vaccine **2010**; 28(3): 754-8.

23. Eberly MD, Gorman GH, Eide MB, Olsen CH, Rajnik M. The effect of rotavirus immunization on rotavirus gastroenteritis hospitalization rates in military dependents. Vaccine **2011**; 29(4): 650-9.

24. Garcia-Puebla A, Garcia-Fragoso L. Acute rotavirus gastroenteritis in children younger than 5 years of age after initiation of rotavirus immunization schedule. Bol Asoc Med P R **2012**; 104(1): 4-7.

25. Lopman BA, Curns AT, Yen C, Parashar UD. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis **2011**; 204(7): 980-6.

26. Guerra AH, Stockmann C, Pavia AT, et al. Laboratory-Confirmed Rotavirus Disease in Utah Children: Clinical and Economic Impact of Rotavirus Vaccination. J Pediatric Infect Dis Soc **2012**; 1(4): 268-77.

27. Leshem E, Moritz RE, Curns AT, et al. Rotavirus vaccines and health care utilization for diarrhea in the United States (2007-2011). Pediatrics **2014**; 134(1): 15-23.

28. Calello DP, Allegra SJ, Cochrane DG, Eskin B, Allegra JR. Emergency Department Visits for Gastroenteritis Before and After Rotavirus Vaccine Implementation in 2006. Pediatr Emerg Care **2015**; 31(10): 699-700.

29. Leshem E, Tate JE, Steiner CA, Curns AT, Lopman BA, Parashar UD. Acute gastroenteritis hospitalizations among US children following implementation of the rotavirus vaccine. JAMA **2015**; 313(22): 2282-4.

30. Shah MP, Tate JE, Steiner CA, Parashar UD. Decline in Emergency Department Visits for Acute Gastroenteritis among Children in 10 US States Following Implementation of Rotavirus Vaccination, 2003-2013. Pediatr Infect Dis J **2016**.

31. Sahakyan G, Grigoryan S, Wasley A, et al. Impact and Effectiveness of Monovalent Rotavirus Vaccine in Armenian Children. Clin Infect Dis **2016**; 62 Suppl 2: S147-54.

32. Safadi MA, Berezin EN, Munford V, et al. Hospital-based surveillance to evaluate the impact of rotavirus vaccination in Sao Paulo, Brazil. Pediatr Infect Dis J **2010**; 29(11): 1019-22.

33. do Carmo GM, Yen C, Cortes J, et al. Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLoS Med **2011**; 8(4): e1001024.

34. Gurgel RQ, Ilozue C, Correia JB, Centenari C, Oliveira SM, Cuevas LE. Impact of rotavirus vaccination on diarrhoea mortality and hospital admissions in Brazil. Trop Med Int Health **2011**; 16(9): 1180-4.

35. Montenegro FM, Falbo AR, Germano EM, et al. Reduction in Rotavirus Disease and Sustained Predominance of G2P[4] Rotavirus Strain following Introduction of Rotavirus Vaccine in Recife, Brazil. J Trop Pediatr **2015**; 61(3): 206-9.

36. Paternina-Caicedo A, Parashar UD, Alvis-Guzman N, et al. Effect of rotavirus vaccine on childhood diarrhea mortality in five Latin American countries. Vaccine **2015**; 33(32): 3923-8.

37. Costa I, Linhares AC, Cunha MH, et al. Sustained Decrease in Gastroenteritis-related Deaths and Hospitalizations in Children Less Than 5 Years of Age After the Introduction of Rotavirus Vaccination: A Time-Trend Analysis in Brazil (2001-2010). Pediatr Infect Dis J **2016**; 35(6): e180-90.

38. Paulo RL, Rodrigues AB, Machado BM, Gilio AE. The impact of rotavirus vaccination on emergency department visits and hospital admissions for acute diarrhea in children under 5 years. Rev Assoc Med Bras (1992) **2016**; 62(6): 506-12.

39. De Oliveira LH, Giglio N, Ciapponi A, et al. Temporal trends in diarrhea-related hospitalizations and deaths in children under age 5 before and after the introduction of the rotavirus vaccine in four Latin American countries. Vaccine **2013**; 31 Suppl 3: C99-108.

40. Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med **2010**; 362(4): 299-305.

41. Gastanaduy PA, Sanchez-Uribe E, Esparza-Aguilar M, et al. Effect of rotavirus vaccine on diarrhea mortality in different socioeconomic regions of Mexico. Pediatrics **2013**; 131(4): e1115-20.

42. Esparza-Aguilar M, Gastanaduy PA, Sanchez-Uribe E, et al. Diarrhoea-related hospitalizations in children before and after implementation of monovalent rotavirus vaccination in Mexico. Bull World Health Organ **2014**; 92(2): 117-25.

43. Sanchez-Uribe E, Esparza-Aguilar M, Parashar UD, Richardson V. Sustained Reduction of Childhood Diarrhea-Related Mortality and Hospitalizations in Mexico After Rotavirus Vaccine Universalization. Clin Infect Dis **2016**; 62 Suppl 2: S133-9.

44. Gheorghita S, Birca L, Donos A, et al. Impact of Rotavirus Vaccine Introduction and Vaccine Effectiveness in the Republic of Moldova. Clin Infect Dis **2016**; 62 Suppl 2: S140-6.

45. Bayard V, DeAntonio R, Contreras R, et al. Impact of rotavirus vaccination on childhood gastroenteritis-related mortality and hospital discharges in Panama. Int J Infect Dis **2012**; 16(2): e94-8.

46. Molto Y, Cortes JE, De Oliveira LH, et al. Reduction of diarrhea-associated hospitalizations among children aged < 5 Years in Panama following the introduction of rotavirus vaccine. Pediatr Infect Dis J **2011**; 30(1 Suppl): S16-20.

47. Enane LA, Gastanaduy PA, Goldfarb DM, et al. Impact of Rotavirus Vaccination on Hospitalizations and Deaths From Childhood Gastroenteritis in Botswana. Clin Infect Dis **2016**; 62 Suppl 2: S168-74.

48. Enweronu-Laryea CC, Boamah I, Sifah E, Diamenu SK, Armah G. Decline in severe diarrhea hospitalizations after the introduction of rotavirus vaccination in Ghana: a prevalence study. BMC Infect Dis **2014**; 14: 431.

49. Armah G, Pringle K, Enweronu-Laryea CC, et al. Impact and Effectiveness of Monovalent Rotavirus Vaccine Against Severe Rotavirus Diarrhea in Ghana. Clin Infect Dis **2016**; 62 Suppl 2: S200-7.

50. Bar-Zeev N, Jere KC, Bennett A, et al. Population Impact and Effectiveness of Monovalent Rotavirus Vaccination in Urban Malawian Children 3 Years After Vaccine Introduction: Ecological and Case-Control Analyses. Clin Infect Dis **2016**; 62 Suppl 2: S213-9.

51. Benhafid M, Elomari N, Azzouzi Idrissi M, et al. Effect of monovalent rotavirus vaccine on rotavirus disease burden and circulating rotavirus strains among children in Morocco. J Med Virol **2015**; 87(6): 944-53.

52. Ngabo F, Tate JE, Gatera M, et al. Effect of pentavalent rotavirus vaccine introduction on hospital admissions for diarrhoea and rotavirus in children in Rwanda: a time-series analysis. Lancet Glob Health **2016**; 4(2): e129-36.

53. Groome MJ, Zell ER, Solomon F, et al. Temporal Association of Rotavirus Vaccine Introduction and Reduction in All-Cause Childhood Diarrheal Hospitalizations in South Africa. Clin Infect Dis **2016**; 62 Suppl 2: S188-95.

54. Abeid KA, Jani B, Cortese MM, et al. Monovalent Rotavirus Vaccine Effectiveness and Impact on Rotavirus Hospitalizations in Zanzibar, Tanzania: Data from the First 3 Years Post-Introduction. J Infect Dis **2016**.

55. Tsolenyanu E, Mwenda JM, Dagnra A, et al. Early Evidence of Impact of Monovalent Rotavirus Vaccine in Togo. Clin Infect Dis **2016**; 62 Suppl 2: S196-9.

56. Banajeh SM, Abu-Asba BA. The epidemiology of all-cause and rotavirus acute gastroenteritis and the characteristics of rotavirus circulating strains before and after rotavirus vaccine introduction in Yemen: analysis of hospital-based surveillance data. BMC Infect Dis **2015**; 15: 418.

57. Amood Al-Kamarany M, Al-Areqi L, Mujally A, Alkarshy F, Nasser A, Jumaan AO. Diarrheal Diseases Hospitalization in Yemen before and after Rotavirus Vaccination. Scientifica (Cairo) **2016**; 2016: 8485417.

58. Mpabalwani EM, Simwaka CJ, Mwenda JM, et al. Impact of Rotavirus Vaccination on Diarrheal Hospitalizations in Children Aged <5 Years in Lusaka, Zambia. Clin Infect Dis **2016**; 62 Suppl 2: S183-7.